Influence of post-transplant recombinant human granulocyte colony-stimulating factor administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation


Demirer T., Ayli M., Dagli M., Haznedar R., Genc Y., Fen T., ...Daha Fazla

BRITISH JOURNAL OF HAEMATOLOGY, cilt.118, ss.1104-1111, 2002 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 118 Konu: 4
  • Basım Tarihi: 2002
  • Doi Numarası: 10.1046/j.1365-2141.2002.03762.x
  • Dergi Adı: BRITISH JOURNAL OF HAEMATOLOGY
  • Sayfa Sayıları: ss.1104-1111

Özet

This study evaluated of the effect of post-transplant recombinant human granulocyte colony-stimulating factor (rhG-CSF) administration on the parameters of peritransplant morbidity. Three sequential and consecutive cohorts of 20 patients each received either post-transplant rhG-CSF at a dose of 5 mug/kg/d i.v. in the morning, starting on d 0, d 5, or no rhG-CSF. Patients who received rhG-CSF starting on d 0 and 5 recovered granulocytes more rapidly than those not receiving rhG-CSF (P < 0.001 for ANC greater than or equal to 0.5 and 1 x 10(9) /l). RhG-CSF administration was not significantly associated with more rapid platelet engraftment. RhG-CSF administration starting on d 0 and 5 was significantly associated with a decreased duration of fever (P = 0.002 and 0.001 respectively), antibiotic administration (P < 0.001 and 0.006 respectively) and shorter hospitalization (P < 0.001 and 0.001 respectively) compared with the reference group. There was no difference between the d 0 and d 5 arms regarding the parameters of peritransplant morbidity. In conclusion, rhG-CSF administration was associated with a faster granulocyte recovery, shorter hospitalization, and shorter period of fever and non-prophylactic antibiotic administration. This study also showed that starting rhG-CSF administration on d 5 may be as effective as d 0 on the clinical outcome and may be an economical approach in routine clinical practice in this cost-conscious era.